Neuraptive Therapeutics, Inc.
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The Company’s franchise therapeutics product is designed for administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves. Also, the Company is developing a suite of advanced microsurgical instruments for use in peripheral nerve surgery.
NTX-001 is a combination drug-device product and 505(b)2. Neuraptive plans to initiate Phase 2 clinical studies shortly in the US.
NTX-001 is being developed to address a wide range of clinical presentations in which patients require surgical repair of the nerve. Market opportunities include acute trauma patients as well as patients undergoing corrective, reconstructive, and elective surgeries. Reimbursements for nerve repair procedures are well-established and significant. Neuraptive’s products address a ~$2.2B US and >$5.5B global market opportunity.
The in-licensed and issued patent estate from the University of Texas protects the method of repairing nerves embodied in NTX-001. Neuraptive has invented a novel delivery device, a formulation and a kit design for which separate patent applications have been filed. Patent protections is expected to extend through 2038.